Dr. Ari J. Rosenberg, MD
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave # Mc2115
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 207
Licensed in Illinois since 2015, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036138973 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 207
- Services billed
- 687
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 287 | 125 |
| New patient office or other outpatient visit, 60-74 minutes | 47 | 47 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 38 | 19 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 25 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 25 | 24 |
| Hospital discharge day management, 30 minutes or less | 18 | 15 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Chicago, IL | 73 |
| Lenvima (lenvatinib mesylate) | 25 |
| Cabometyx (cabozantinib s-malate) | 24 |
| Gabapentin Other prescribers in Chicago, IL | 12 |
| Tafinlar (dabrafenib mesylate) | 11 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Chicago, IL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $8,454 in total to this clinician.
| Janssen Global Services, LLC | $6,206 |
|---|---|
| Janssen Scientific Affairs, LLC | $2,115 |
| Gilead Sciences, Inc. | $133 |
| Consulting Fee | $7,915 |
|---|---|
| Travel and Lodging | $384 |
| Food and Beverage | $155 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Global Services, LLC Nov 21, 2025 | Consulting Fee RYBREVANT · Oncology | $3,625 |
| Janssen Global Services, LLC Oct 17, 2025 | Consulting Fee RYBREVANT · Oncology | $2,175 |
| Janssen Scientific Affairs, LLC Dec 18, 2025 | Consulting Fee RYBREVANT · Oncology | $2,115 |
| Janssen Global Services, LLC Oct 16, 2025 | Travel and Lodging RYBREVANT · Oncology · travel to BERLIN, Germany · in-kind | $384 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 9 companies. The companies reported $701,031 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Janssen Research & Development, LLC - Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Beigene Switzerland GmbH · Recruiting · NCT05526924 - An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development - Cisplatin-ineligible locoregionally advanced head and neck cancer: A real-world evidence analysis.
EMD Serono Research & Development Institute, Inc. - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - A phase 1 study of SGNB6A in advanced solid tumors
Pfizer Inc. - A phase 2, randomized, open-label, platform study using a master proto
GlaxoSmithKline, LLC. - CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals, Inc. · Terminated · NCT04633278 - Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
Beone Medicines USA, Inc. · Completed · NCT03744468
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.